| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We produced depressive model rats by exposure of chronic corticosterone treatment and refractory depression model rats by alcohol exposure during the fetal period followed by the corticosterone treatment during adolescent. Treatment with escitalopram reversed depression-like behavior in refractory depression model accompanied by the reduction of BDNF levels in serum. We analyzed the influence of alcohol drinking on the therapeutic effects of antidepressants and evaluated that co-occurrence of major depressive disorder and alcohol use disorder is associated with a lower response to antidepressant treatment. We also investigated the effect of Lysophosphatidic acid (LPA) on the viability of rat C6 glioma cells and found that an LPA receptor antagonist, BrP-LPA, competitively blocked the LPA-induced reduction of C6 cell viability through LPA receptors. These findings support the hypothesis that LPA plays important roles in astrocyte-mediated brain network impairment.
|
